USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/6057
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUstian, Aurelia
dc.contributor.authorMalic, Alina
dc.contributor.authorLesnic, Evelina
dc.date.accessioned2019-06-26T12:33:11Z-
dc.date.available2019-06-26T12:33:11Z-
dc.date.issued2016
dc.identifier.citationAspectele clinico-radiologice, microbiologice şi eficacitatea tratamentului la pacienţi cu tuberculoza pulmonară diagnosticaţi prin Xpert MTB/Rif / Aurelia Ustian, Valeriu Crudu, Alina Malic [et al.] // Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale. - 2016. - Nr. 1(50). - P. 59-62. - Bibliogr.: p. 62.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/6057-
dc.descriptionIP USMF „Nicolae Testemiţanu”, IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc”en_US
dc.description.abstractXpert MTB/Rif este un test nou molecular pentru diagnosticarea precoce а tuberculozei și aprecierea rezistenței la unul din cele mai importante preparate antituberculoase - rifampicină. Scopul studiului a fost aprecierea aspectelor clinicoradiologice, microbiologice şi efi cacităţii tratamentului la pacienţi cu tuberculoză pulmonară diagnosticaţi prin Xpert MTB/Rif. A fost studiat un lot de 310 pacienţi cu tuberculoză pulmonară tratați la Spitalul clinic municipal de tuberculoză în 2014. Bolnavii au fost distribuiți în 2 eşantioane: eşantion I – 123 bolnavii cu rezultatul pozitiv Xpert MTB/Rif, sensibil la rifampicină şi eşantion II – 187 bolnavi cu Xpert MTB/Rif negativ. Sputa microscopic pozitivă a fost determinată în 72 (58,5%) cazuri în eşantionul I şi numai la 9 (4,8%) bolnavi - în eşantionul II, p<0,001. Cultura a fost pozitivă la 103 (83,7%) pacienţi în eșantionul I şi la 15 (8%) bolnavi în eşantionul II, p<0,001. Succesul tratamentului (vindecat și tratament încheiat) în eşantionul I a fost stabilit în 77,3%, iar în eşantionul II – în 85,6% cazuri. Clinical, radiological, microbiological aspects and treatment effi cacy in pulmonary TB patients diagnosed by Xpert MTB/Rif Xpert MTB/Rif is a new molecular test for early TB diagnosis and assessment of resistance to the one of the most important antituberculosis drug - rifampicin. The aim of the study was to evaluate the clinical, radiological, microbiological aspects and treatment effi cacy in TB pulmonary patients diagnosed by Xpert MTB/Rif. Were studied a group of 310 pulmonary tuberculosis patients, treated in the IMSP SCMF, in 2014. Patients were distributed in two groups: 1st group - 123 patients with positive result Xpert MTB/ RIF, sensitive to rifampicin and 2nd group - 187 patients with Xpert MTB/ Rif negative. Sputum microscopy was positive in 72 (58.5%) cases in the 1st group and only in 9 (4.8%) patients in the 2nd group, p <0.001. Сulture was positive in 103 (83.7%) cases in the 1st group, and in 15 (8%) cases - in the 2nd group, p <0.001. Treatment success (cured and treatment completed) rate was 77, 3% in the 1st group and 85.6% - in the 2nd group. Клинико-рентгенологические, микробиологические аспекты и эффективность лечения у пациентов с туберкулезом легких диагностированных Xpert MTB/RIF Xpert MTB/RIF – новый молекулярный тест для ранней диагностики туберкулеза и оценки устойчивости к одному из наиболее эффективных противотуберкулезных препаратов – рифампицину. Цель исследования – оценка клинико-рентгенологических, микробиологических аспектов и эффективности лечения у пациентов с туберкулезом легких диагностированных посредством Xpert MTB/RIF. В ходе исследования были изучены данные 310 больных туберкулезом легких, лечившихся в Муниципальной Клинической Фтизиопульмонологической больнице Кишинева, в 2014 г. Пациенты были распределены на две группы: I группа – 123 больных с положительным результатом Xpert MTB/RIF, чувствительным к рифампицину и II группа – 187 больных с отрицательным результатом Xpert MTB/RIF. Микроскопия мокроты была положительной у 72 (58,5%) больных I-й группы и у 9 (4,8%) пациентов II-й группы, р<0,001. Культура была положительной у 103 (83,7%) пациентов из I-й группы, и у 15 (8%) больных II-й группы, р <0,001. Успешное лечение (излечение и законченное лечение) в I-й группе составило 77, 3%, а во II-й группе – 85,6%.en_US
dc.language.isoroen_US
dc.publisherBuletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicaleen_US
dc.subject.meshTuberculosis, Pulmonary - drug therapyen_US
dc.subject.meshTuberculosis, Pulmonary - microbiologyen_US
dc.subject.meshRifampin - therapeutic useen_US
dc.titleAspectele clinico-radiologice, microbiologice şi eficacitatea tratamentului la pacienţi cu tuberculoza pulmonară diagnosticaţi prin Xpert MTB/Rifen_US
dc.title.alternativeClinical, radiological, microbiological aspects and treatment effi cacy in pulmonary TB patients diagnosed by Xpert MTB/Rifen_US
dc.title.alternativeКлинико-рентгенологические, микробиологические аспекты и эффективность лечения у пациентов с туберкулезом легких диагностированных Xpert MTB/RIFen_US
dc.typeArticleen_US
Appears in Collections:ARTICOLE ȘTIINȚIFICE



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback